Schneider et al. showed that the FLT3-ITD mRNA level has a high prognostic impact in NPM1-mutated AML-NK, and that it contributes to relapse risk stratification and might help to guide postremission therapy in NPM1- mutated AML [29]. This evidence concerns the gene FLT3 and acute myeloid leukemia.